Nam libero tempore, cum soluta nobis eligendi cumque quod placeat facere possimus assumenda omnis dolor repellendu sautem temporibus officiis
5689 Lotaso Terrace, Culver City,
CA, United States
The SURMOUNT-4 phase 3 clinical trial found that anti-obesity drugs may require long-term use to maintain weight loss. Like diabetes or high blood pressure, obesity may need to be treated chronically. Credit: Shutterstock The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led […]
BACKGROUND Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; […]
INDIANAPOLIS, April 27, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2. The study met both co-primary objectives and all key secondary objectives for tirzepatide compared to placebo for both estimandsi. Those taking tirzepatide […]
